Pharmacotherapy for chronic myelogenous leukemia: A case-based approach Journal Article


Author: Harnicar, S.
Article Title: Pharmacotherapy for chronic myelogenous leukemia: A case-based approach
Abstract: TKIs have become the standard of care for CML. Imatinib was the first to transform the outcomes of this disease. Dasatinib and nilotinib were recently added to the armamentarium for imatinib-resistant disease and, more recently, for first-line therapy. When choosing a TKI for patients, adverse effects, presence of mutations in the BCR-ABL kinase domain, and cost should be considered. Once chosen, drug interactions should be evaluated for all patients. New drugs are being studied to prevent disease progression and for patients with T315I mutations. This article reviews the pharmacotherapy of CML with the aid of a patient case. © JNCCN-Journal of the National Comprehensive Cancer Network.
Keywords: cancer chemotherapy; cancer survival; treatment outcome; gene mutation; busulfan; hydroxyurea; drug tolerability; fatigue; neutropenia; review; diarrhea; drug dose reduction; drug efficacy; gastrointestinal hemorrhage; side effect; alpha interferon; cytarabine; drug megadose; imatinib; edema; liver toxicity; anemia; bone marrow suppression; gastrointestinal symptom; nausea; thrombocytopenia; vomiting; incidence; qt prolongation; cml; dasatinib; chronic myeloid leukemia; tyrosine kinase inhibitors; protein tyrosine kinase inhibitor; dyspnea; pneumonia; rash; drug cost; paracetamol; proton pump inhibitor; cardiotoxicity; fusion gene; patient compliance; pleura effusion; headache; drug metabolism; bcr abl protein; clarithromycin; ketoconazole; levothyroxine; toxicity; nilotinib; pericardial effusion; levofloxacin; rifampicin; verapamil; brain hemorrhage; congestive heart failure; leg edema; voriconazole; homoharringtonine; allotransplantation; chronic myelogenous leukemia; sudden death; pantoprazole; pharmacotherapy; bosutinib; ritonavir
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 9
Issue: Suppl. 3
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2011-02-01
Start Page: S25
End Page: S35
Language: English
PROVIDER: scopus
PUBMED: 21357665
DOI/URL:
Notes: --- - "Export Date: 23 June 2011" - "Source: Scopus"
Citation Impact
MSK Authors